HX009
As of the edition of 20 October 2026, HX009 is a drug known only by a code name: of no established status; acts on CD47 and PDCD1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Status not established
- Kind
- Code name only
- Registered trials
- 3, 0 stopped early
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 0 |
| Phase 2 | 1 | 1 | 0 | 0 |
| All trials | 3 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Waterstone Hanxbio | Lead sponsor of trials | 2019 to now |
| Hangzhou Hanx Biopharmaceuticals | Lead sponsor of trials | 2020 to now |